scispace - formally typeset
B

Bin Chen

Researcher at Michigan State University

Publications -  95
Citations -  3116

Bin Chen is an academic researcher from Michigan State University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 25, co-authored 80 publications receiving 2386 citations. Previous affiliations of Bin Chen include East China University of Science and Technology & Indiana University.

Papers
More filters
Journal ArticleDOI

A survey of current trends in computational drug repositioning

TL;DR: This review of recent advancements in the critical areas of computational drug repositioning from multiple aspects shows potential opportunities and use-cases, including a few target areas such as cancers.
Journal ArticleDOI

Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data

TL;DR: The utility of Chem2Bio2RDF is demonstrated in investigating polypharmacology, identification of potential multiple pathway inhibitors, and the association of pathways with adverse drug reactions, as well as extending SPARQL with cheminformatics and bioinformatics functionality.
Journal ArticleDOI

Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis.

TL;DR: This work presents a workflow that leverages data from chemogenomics based target predictions with Systems Biology databases to better understand off-target related toxicities and links between pathways and particular adverse effects are established.
Journal ArticleDOI

Assessing Drug Target Association Using Semantic Linked Data

TL;DR: A statistical model to assess the association of drug target pairs based on their relation with other linked objects is developed, providing a novel, validated alternative to existing drug target prediction algorithms.
Journal ArticleDOI

Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

TL;DR: It is shown that the potency of a drug to reverse cancer-associated gene expression changes positively correlates with that drug’s efficacy in preclinical models of breast, liver and colon cancers and may be complementary to the traditional target-based approach in connecting diseases to potentially efficacious drugs.